|
Nutraceutical News
PRESS RELEASE ARCHIVES FROM SEND2PRESS® NEWSWIRE
NOTICE: THIS IS ARCHIVAL CONTENT AND LIKELY OUT OF DATE.
Nutraceutical Leader Sterling Grant Laboratories Launches Nicotine Free NicCess Lozenges
Article Editor: Carly Zander
FAIRFIELD, NJ - December 31, 2004 /Send2Press Newswire/ -- Leading Nutraceutical manufacturer Sterling Grant Laboratories has entered the crowded smoke cessation market with a nicotine free lozenge, NicCess. The active ingredient in NicCess, Cesteminol 350, has been shown to be statistically effective in as little as 21 days and no later than 37 days.
Company V.P. of Marketing Dean Spinogatti said, "This product is already getting interest from the large pharmaceutical companies. NicCess has two patents and one patent pending for nutrient delivery. This product flat out works and has the research to back it up!"
NicCess seems to be an excellent alternative to the nicotine containing products that are currently being marketed in this class. NicCess is simple to use and safe. All you have to do is replace one cigarette with one lozenge.
Sterling Grant will be marketing this product in multiple channels and distributing it in national chains by mid 2005. NicCess is currently available at NicCess.com and Nutrazone.net.
Organization Website(s):
www.Nutrazone.net
Source of News:
Sterling Grant Laboratories
THIS IS ARCHIVAL CONTENT
Note: for contact information at the organization mentioned in the above PRESS RELEASE, visit the "organization website" (if applicable), or view either version of the original news release using the links below. Send2Press cannot provide contact info.
Business News is powered by
eNewsChannels™
Viewed by the media ***
References:
Sterling Labs, stop smoking, smoke cessation, quitting smoking, quit smoking, nicotine, nicotine addiction, non nicotine smoke cessation, stop smoking lozenge.
USE OF THE ABOVE NEWS ARTICLE
News is Copr. © 2004 Neotrope/Send2Press. Reproduction of this news article in any form requires written authorization. You may freely link to this article, or republish the "news release" text version linked to above under "Journalist Tools" without restriction except websites must retain /Send2Press Newswire/ as the source. Sites which offer/sell PR services or newswire services may not reprint our content without express written permission.
FOR INFORMATION ABOUT THE ORGANIZATION(S) MENTIONED IN THE ABOVE NEWS ARTICLE, PLEASE CONTACT THE COMPANY DIRECTLY AND NOT THIS WEBSITE.
DISCLAIMER: the above article is believed accurate but not guaranteed, and is based on business news supplied by the organization mentioned and/or quoted in the story. The organization providing the news to Send2Press is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements and public companies should be thoroughly researched before considering material investment. Neotrope/Send2Press makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news item are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope/Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.
|
